Monitor warrant exercise activity as it could bring meaningful capital without additional dilution. The shelf registration enables future opportunistic offerings, but current financials and recent positive developments suggest this is precautionary rather than urgent. Watch for clinical trial progress as catalysts.
Price Chart
Executive Summary
Tempest Therapeutics filed an S-3 shelf registration to register 2,777,781 shares for resale by selling stockholders, including shares issued in a recent private placement and shares issuable upon warrant exercise. The company will not receive proceeds from the resale, but may receive up to $4 million from warrant exercises. This follows strong clinical data and a strategic acquisition, suggesting opportunistic capital raising rather than distress.
Key Financial Metrics
Key Facts
- S-3 shelf registration for 2,777,781 shares to be resold by selling stockholders
- Shares include 462,964 common shares and 2,314,817 shares issuable upon warrant exercise
- Company will not receive proceeds from share resale but may receive $4 million from warrant exercises
- Recent positive clinical data for TPST-2003 in multiple myeloma and acquisition of CAR-T assets
- Company had $7.7 million cash at year-end 2025 with net loss decreasing to $26.3 million
Financial Impact
Up to $4 million potential proceeds from warrant exercises at $2.16 per share; no proceeds from share resale
Risk Factors
- Potential dilution if warrants are exercised
- Biotech development risk for clinical-stage assets
- Small market cap ($23M) increases volatility risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-138652 |
| Document: d17525dexfilingfees.htm | 0001193125-26-138652 |
| Document: d17525dex51.htm | 0001193125-26-138652 |
| Document: d17525dex231.htm | 0001193125-26-138652 |
| Document: 0001193125-26-138652-index-headers.html | 0001193125-26-138652 |
| Document: 0001193125-26-138652-index.html | 0001193125-26-138652 |
| Document: 0001193125-26-138652.txt | 0001193125-26-138652 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5110 (−11.32%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers